The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.

Wang J, Li HQ, Xu XH, Kong XC, Sun R, Jing T, Ye L, Su XF, Ma JH

BioMed research international24 Dec 2019Cited by 21 (Europe PMC)

PMID31950036PMCIDPMC6943972DOI10.1155/2019/2682657PepBankPUB-31950036

Summary

Aim. To compare the effects of once-weekly Dulaglutide with once-daily glargine in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus (T2DM). Method. A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9). All patients received either Dulaglutide or glargine treatments for 52 weeks. Continuous glucose monitoring systems (CGMS) were applied to them for two 72 h periods at before and after the treatment each. Patient general clinical data were collected and analyzed. Result. Fast blood glucose (FBG) of the glargine group declined more significantly than the Dulaglutide group after treatment (p < 0.05). The mean blood glucose (MBG), standard deviation of blood glucose (SDBG), mean amplitude of glycemic excursion (MAGE) within a day, the largest amplitude of glycemic excursion (LAGE), M-value, absolute means of daily difference (MODD) of glycemic excursion, the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05). The incidence of hypoglycemia was also similar between the two groups (p > 0.05). Though serum levels of TNF-α, IL-6, and 8-PGF2α all decreased, significant reduction was found in TNF-α and 8-PGF2α. TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2α was seen in both groups. Conclusion. For T2DM patients with poorly controlled oral antidiabetic drugs, once-weekly Dulaglutide not only has the same effect on glucose fluctuation as once-daily glargine but also significantly reduced TNF-α and 8-PGF2α after a 52 week treatment protocol. This trial is registered with ClinicalTrials.gov NCT01648582.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study19

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, fasting blood glucose declined less with dulaglutide than glargine.
In plain wordsIn patients with T2DM, fasting blood sugar fell less with dulaglutide than glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseFasting blood glucose
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
Fast blood glucose (FBG) of the glargine group declined more significantly than the Dulaglutide group after treatment (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003601
02HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, mean blood glucose was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, average blood sugar was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeMean blood glucose
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
The mean blood glucose (MBG),
3 context sentences(design, population, supporting numbers)
Summary · context
were similar between the two groups (p > 0.05).
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003602
03HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, blood glucose standard deviation was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, blood sugar variation was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeStandard deviation of blood glucose
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
standard deviation of blood glucose (SDBG),
3 context sentences(design, population, supporting numbers)
Summary · context
were similar between the two groups (p > 0.05).
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003603
04HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, MAGE was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, average blood sugar swings were similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeMean amplitude of glycemic excursion
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
mean amplitude of glycemic excursion (MAGE) within a day,
3 context sentences(design, population, supporting numbers)
Summary · context
were similar between the two groups (p > 0.05).
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003604
05HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, LAGE was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, the largest blood sugar swings were similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLargest amplitude of glycemic excursion
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the largest amplitude of glycemic excursion (LAGE),
3 context sentences(design, population, supporting numbers)
Summary · context
were similar between the two groups (p > 0.05).
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003605
06HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, M-value was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, M-value was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeM-value
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
M-value, absolute means of daily difference (MODD) of glycemic excursion,
3 context sentences(design, population, supporting numbers)
Summary · context
were similar between the two groups (p > 0.05).
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003606
07HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, MODD was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, daily blood sugar differences were similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAbsolute means of daily difference
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
absolute means of daily difference (MODD) of glycemic excursion,
3 context sentences(design, population, supporting numbers)
Summary · context
were similar between the two groups (p > 0.05).
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003607
08HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, time at glucose ≤2.8 mmol/L was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, time at glucose ≤2.8 mmol/L was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTime at glucose ≤2.8 mmol/L
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003608
09HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, time at glucose ≤3.9 mmol/L was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, time at glucose ≤3.9 mmol/L was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTime at glucose ≤3.9 mmol/L
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003609
10HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, time at glucose ≥10.0 mmol/L was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, time at glucose ≥10.0 mmol/L was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTime at glucose ≥10.0 mmol/L
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003610
11HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, time at glucose ≥13.9 mmol/L was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, time at glucose ≥13.9 mmol/L was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTime at glucose ≥13.9 mmol/L
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003611
12HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, time at glucose 3.9-7.8 mmol/L was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, time at glucose 3.9-7.8 mmol/L was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTime at glucose 3.9-7.8 mmol/L
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003612
13HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, time at glucose 9-10.0 mmol/L was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, time at glucose 9-10.0 mmol/L was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTime at glucose 9-10.0 mmol/L
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9-7.8 mmol/L, and 9-10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003613
14HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, maximum glucose was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, maximum blood sugar was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeMaximum glycemic value
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
maximum glycemic value, and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003614
15HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, minimum glucose was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, minimum blood sugar was similar with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeMinimum glycemic value
Study
n = 25
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
and minimum glycemic value were similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003615
16HumanRandomized controlled trialSafety outcome
In patients with T2DM, hypoglycemia incidence was similar with dulaglutide and glargine.
In plain wordsIn patients with T2DM, low blood sugar occurred at similar rates with dulaglutide and glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHypoglycemia incidence
Study
n = 25
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
The incidence of hypoglycemia was also similar between the two groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003616
17HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, TNF-alpha decreased significantly only in the dulaglutide group.
In plain wordsIn patients with T2DM, TNF-alpha fell significantly from baseline only in the dulaglutide group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-alpha
Study
n = 16
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2α was seen in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
Show in the study text Report a problemFND-3195003617

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

18HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with T2DM, 8-PGF2alpha decreased significantly in both dulaglutide and glargine groups.
In plain wordsIn patients with T2DM, 8-PGF2α fell significantly in both the dulaglutide and glargine groups.
Peptide
Dulaglutide (Trulicity)
Outcome
Decrease8-PGF2alpha
Study
n = 25
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2α was seen in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3195003618
19HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In patients with T2DM, serum IL-6 decreased, but the abstract reports significant reductions only for TNF-alpha and 8-PGF2alpha.
In plain wordsIn patients with T2DM, IL-6 fell, but the fall was not reported as significant.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeIL-6
Study
n = 25
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Though serum levels of TNF-α, IL-6, and 8-PGF2α all decreased, significant reduction was found in TNF-α and 8-PGF2α.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n = 16) and glargine group (n = 9).
Summary · context
All patients received either Dulaglutide or glargine treatments for 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3195003619

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.